Retatrutide — Vital Edge Science
Brand Vital Edge Science100 followers
$78.00

In Stock

Retatrutide (code LY3437943) is an unapproved Eli Lilly peptide that targets the GLP-1, GIP and glucagon receptors together, sold here only as freeze-dried material for laboratory research.

  • Third-party report: Attached
  • Dispatches from: Australia
Bulk pricingCombine any Vital Edge Science products: each kit from this vendor counts toward your discount tier.
  1. 1–4 kits$78.00full price
  2. 5+ kits$74.105% off
  3. 10+ kits$70.2010% off
  4. 20+ kits$68.6412% off
  5. 50+ kits$66.3015% off
  6. 100+ kits$62.4020% off
ß

Minimum order $100.00 across all brands, before the escrow fee.

◆
Escrow-protected purchaseYour payment is held by us — the brand is only paid after you confirm delivery.
↺
Refund if not deliveredOpen a claim from your order page; upheld claims are refunded to your Escrow Wallet.
✓
Sold by Vital Edge ScienceVetted vendor · ships from Australia New Zealand
⚗
Lab testingJanoshik #101556 · 99.36% purity · Jan 23, 2026
View report · How to read it · All reports

For research use only. Not for human consumption. Not medical advice.

Log in to watch this price

Sold by Vital Edge Science: a kit of Retatrutide, dispatched from Australia. The kit costs $78.00. Checkout is escrow-protected: Vital Edge Science is paid once you mark the order as delivered.

This listing: Vital Edge Science Retatrutide

Lab testing

Vital Edge Science published a Janoshik #101556 report for this compound. Test: Purity (HPLC). Result: 99.36% purity. Tested Jan 23, 2026. Verification key 4XI5S41HDDX9 can be checked at janoshik.com.

View the report · How to read it (Testing 101) · Every report for this compound

Bought through escrow: the brand is only paid after you confirm delivery. If the parcel never arrives, or an independent test shows the wrong compound or a significant under-fill, open a claim before releasing payment.

About Retatrutide

Retatrutide, also known by the development code LY3437943, is a long synthetic peptide engineered to act on three receptors at the same time: GLP-1, GIP and glucagon. Its backbone carries a fatty-acid side chain, a common design trick that lets it ride on serum albumin and stay in circulation far longer than a bare peptide would. Its reference molecular weight is about 4731 g/mol (formula C221H342N46O68). The triple-receptor design is what sets it apart from single and dual agonists. Marketplace listings are lyophilized powder intended for in vitro and analytical work.

Areas of study

Researchers approach retatrutide as a way to ask how three hormone signals interact. GLP-1 and GIP receptor activity is associated with glucose-dependent insulin secretion, slower gastric emptying and central appetite pathways. The glucagon arm is the unusual part: it is thought to raise energy expenditure and shift how the liver handles fat, effects scientists try to disentangle from the incretin component. Receptor-binding assays, cell signaling readouts and animal metabolic models are typical settings. How the relative strength of each receptor signal shapes the overall result is still an open and actively debated question.

Where Retatrutide stands

Retatrutide is an investigational medicine. Published mid-stage trials in obesity, type 2 diabetes and fatty liver disease reported substantial changes in weight and liver fat against placebo, and larger late-stage programs have been running since. No regulator has approved it, and long-term safety is not yet established. Anything sold on this marketplace is research material, not a pharmaceutical product. If you cite the clinical work, go to the primary trial papers instead of summaries.

Lab verification

Look for mass spectrometry showing a mass near 4731 g/mol, which indicates the full lipidated molecule and not a shorter or unmodified chain. The report should also include an HPLC chromatogram with a stated purity, measured peptide content against the label, the testing lab, a test date and a batch number matching your vial. The powder should be a white, intact cake. A purity number without an identity result is not enough.

A third-party certificate is on file for this listing, summarised in the testing panel above.

At a glance

Active compound
Retatrutide
Also known as
LY3437943
Peptide class
Investigational triple GLP-1/GIP/glucagon receptor agonist
Form
Lyophilized (freeze-dried) powder
Formula
C221H342N46O68
Molar mass
~4731.3 g/mol
Dispatches from
Australia
Third-party report
Attached

Keeping the vials

Keep the powder sealed and refrigerated or frozen, protected from moisture and light. A reconstituted solution belongs in the fridge, used within the window your study protocol allows.

Questions

Why is per-mg pricing used for retatrutide?

Vial sizes differ between brands, so the sticker price tells you little. Dividing by the milligrams actually in the vial lets you compare like with like. Price alone is a weak signal though; a cheap listing is only a bargain if a recent independent report confirms what is inside.

Where can I find reliable retatrutide research?

Start with the peer-reviewed phase 2 publications and the trial registrations on ClinicalTrials.gov. They set out populations, endpoints and adverse events in full. Community discussion, including in the glp1chat community, is useful for context but should not replace the primary literature.

What exactly is in this kit?

The testing panel above shows what the brand’s tested sample measured.

What happens to my payment?

It stays in escrow until you confirm delivery; only then is it released to Vital Edge Science. If the order is missing or not as described, open a claim before releasing and the held amount can be refunded to your Escrow Wallet.

For in-vitro and laboratory research only. Not for human or veterinary use and not a replacement for any prescribed medicine. Nothing here is medical advice.

Reviews

There are no reviews yet.

0.00

Average of 0 reviews

0 reviews
0 reviews
0 reviews
0 reviews
0 reviews
Be the first to review “Retatrutide”

Your email address will not be published. Required fields are marked *